DexCom (DXCM) Stock: Buy, Sell, or Hold?
$83.33
+1.94 (+2.38%)
▲
5d:
+4.94%
30d:
-4.99%
90d:
-6.12%
QUANTITATIVE VERDICT
BUY
HIGH Confidence (82%)
Quality Score
59/100
Position
FAIR
30-Day Fair Range
$79.76 – $85.81
Position: FAIR
Forward P/E & Valuation
26.6x
FAIR
vs 25.2x historical avg
Wall Street Target
$98.58
+18.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$78.93 / $90.25
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
✅ BUY SIGNAL: DXCM shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
DXCM is flagged by 1 backtest-validated scanner today
SPY Bullish (stocks from this scanner have beaten SPY by a median 0.37% over the next 20 trading days; DXCM has been on it 2 days). Backtested on 8 months of scanner history vs the S&P 500, as of 2026-11-13.
See all of today's Best Signals in the free scanner →Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 21, 2026 at $80.40 · last confirmed Nov 10, 2026
Strength: 3.5/10
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$126.03
Based on 10.1% avg growth
INTRINSIC VALUE TODAY
$78.25
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $83.33, which is considered fair relative to its 30-day fair value range of $79.76 to $85.81. The stock's valuation (Forward PE: 26.6) is in line with its historical norms (25.2). At these levels, the market is pricing in 1.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DXCM is in a downtrend. Immediate support is located at $78.93, while resistance sits at $90.25.
Market Sentiment: DXCM scores 79/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $98.58 (+18.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DXCM is in a downtrend. Immediate support is located at $78.93, while resistance sits at $90.25.
Market Sentiment: DXCM scores 79/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $98.58 (+18.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$79.76 -
$85.81
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.9%
Trading Range & Key Levels
30-Day Trading Range
$79.76 -
$85.81
Current vs Trading Range
FAIR
Support Level
$78.93
Resistance Level
$90.25
Current Trend
Downtrend
Technical data as of
Nov 13, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (79/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($98.58)
- NEUTRAL: Market pricing in 1.8% annual earnings growth - fairly valued
- BULLISH: Bottoming setup score 79/100 — corrected, stabilizing, and turning up
Fundamental Context
Forward P/E (Next Year Est.)
26.58
Wall Street Target
$98.58
(+18.3%)
Revenue Growth (YoY)
11.2%
Earnings Growth (YoY)
2.6%
Profit Margin
19.4%
Valuation Premium vs History
+1.8% premium
PE vs Historical
26.6 vs 25.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.8%
(market-implied from PE analysis)
1-Year Target
$84.83
(+2%)
2-Year Target
$86.36
(+4%)
3-Year Target
$87.91
(+6%)
3-Yr Target (if PE normalizes)
(PE: 27→25)
PE COMPRESSION
$83.34
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.6, Growth: 16.1%)
$130.32
(+56%)
Base:
(SPY PE: 19.9, Growth: 16.1%)
$97.36
(+17%)
Bear:
(PE: 16.9, Growth: 16.1%)
$82.76
(-1%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (27x PE) as earnings recover.
Trailing PE: 32.04 | Current EPS (TTM): $2.54
Bull Case
$110.49
(+33%)
Analyst growth 23.4%, PE expands to 35.3
Base Case
$100.45
(+21%)
Market implied 23.4%, PE stable at 32.0
Bear Case
$55.35
(-34%)
Severe decline -20.0%, PE contracts to 27.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share DXCM Analysis
Share this live DXCM analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (DXCM)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 10, 2026
Daily AI digest
AI Retail Discussion Summary:
Health Canada approves Dexcom G7 for use during pregnancy with myLoop and CamAPS FX, marking a Canadian first for an automated insulin delivery system in pregnancy for type 1 diabetes.
Key Retail Themes:
Regulatory approval
Automated insulin delivery systems
Type 1 diabetes management
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 14, 2026 5:46 AM ET
Data refreshes hourly during market hours. Next update: 6:46 AM
Data refreshes hourly during market hours. Next update: 6:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
BUY
31 analysts |
$50 | 48 HOLD |
|
MDT
Medtronic PLC |
BUY
30 analysts |
$105 | 39 SELL |
|
IRTC
iRhythm Technologies Inc |
STRONG BUY
16 analysts |
$166 | 56 HOLD |
|
PODD
Insulet Corporation |
BUY
26 analysts |
$178 | 45 HOLD |
|
ATEC
Alphatec Holdings Inc |
STRONG BUY
14 analysts |
$13 | 74 BUY |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive DXCM Research Pages
